PMID- 11021768
OWN - NLM
STAT- MEDLINE
DCOM- 20010125
LR  - 20181113
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 23
IP  - 8
DP  - 2000 Sep
TI  - Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with 
      dilated cardiomyopathy.
PG  - 520-5
AB  - Well-nourished patients with dilated cardiomyopathy (DCM) show slight reduction 
      of mean basal IGF-I levels which, however, display a response to a rhGH dose as 
      low as 5.0 microg/kg/day similar to that of age-matched control subjects (CS). To 
      further investigate peripheral GH sensitivity, we studied the IGF-I and IGFBP-3 
      responses to 4-day s.c. 2.5 microg/kg/day rhGH administration, the lowest 
      effective dose able to increase IGF-I levels in normal subjects, in 10 DCM 
      patients [age (mean+/-SE): 57.6+/-1.0 yr, body mass index (BMI): 24.0+/-1.2 
      kg/m2, left ventricular ejection fraction: 26.2+/-3.2%, NYHA (New York Heart 
      Association): I/0, II/4, III/4, IV/2] and in 9 age-matched healthy CS (age: 
      55.3+/-1.2 yr, BMI: 23.7+/-1.8 kg/m2). Basal IGF-I levels in DCM were lower 
      though not significantly than those in CS (147.7+/-9.8 vs 174.7+/-17.0 microg/l). 
      Basal IGFBP-3 levels in DCM were similar to those in CS (3.1+/-0.3 vs 2.7+/-0.2 
      mg/l). In CS 4-day rhGH increased IGF-I levels (222.4+/-14.9 microg/l; p<0.01 vs 
      baseline) but did not modify IGFBP-3 levels (3.0+/-0.2 mg/l). In DCM IGF-I levels 
      were increased by 4-day rhGH administration (175.7+/-11.0 microg/l; p<0.05 vs 
      baseline) with a similar percent extent than in CS. On the other hand, in DCM, 
      but not in CS, 4-day rhGH significantly increased IGFBP-3 levels (3.5+/-0.3 mg/l; 
      p<0.05 vs baseline). Therefore, in conclusion, testing with the lowest effective 
      rhGH dose further suggest that peripheral GH sensitivity in well-nourished DCM is 
      preserved. On the other hand, DCM patients show enhanced IGFBP-3 sensitivity to 
      stimulation by rhGH.
FAU - Broglio, F
AU  - Broglio F
AD  - Dipartimento di Medicina Interna, Universita di Torino, Italy.
FAU - Benso, A
AU  - Benso A
FAU - Arvat, E
AU  - Arvat E
FAU - Aimaretti, G
AU  - Aimaretti G
FAU - Gottero, C
AU  - Gottero C
FAU - Granata, R
AU  - Granata R
FAU - Boghen, M F
AU  - Boghen MF
FAU - Bobbio, M
AU  - Bobbio M
FAU - Camanni, F
AU  - Camanni F
FAU - Ghigo, E
AU  - Ghigo E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Cardiomyopathy, Dilated/*drug therapy
MH  - Human Growth Hormone/*administration & dosage/therapeutic use
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Kinetics
MH  - Male
MH  - Middle Aged
EDAT- 2000/10/06 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/06 11:00
PHST- 2000/10/06 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/06 11:00 [entrez]
AID - 10.1007/BF03343768 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2000 Sep;23(8):520-5. doi: 10.1007/BF03343768.